{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:05:44Z","timestamp":1786568744817,"version":"build-2736575974"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,1,26]],"date-time":"2015-01-26T00:00:00Z","timestamp":1422230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2015,4]]},"abstract":"Abstract<\/jats:title>We previously reported that nab<\/jats:italic>\u2010paclitaxel\u2010based induction chemotherapy (IC<\/jats:styled-content>) and concurrent chemoradiotherapy resulted in low relapse rates (13%) and excellent survival in head and neck squamous cell carcinoma (HNSCC<\/jats:styled-content>). We compare the disease\u2010specific survival (DSS<\/jats:styled-content>) and overall survival (OS<\/jats:styled-content>) between patients given nab<\/jats:italic>\u2010paclitaxel, cisplatin, and fluorouracil with cetuximab (APF<\/jats:styled-content>\u2010C) and historical controls given docetaxel, cisplatin, and fluorouracil with cetuximab (TPF<\/jats:styled-content>\u2010C). Patients with locally advanced HNSCC<\/jats:styled-content> were treated with APF<\/jats:styled-content>\u2010C (n\u00a0<\/jats:italic>=\u00a0<\/jats:italic>30) or TPF<\/jats:styled-content>\u2010C (n\u00a0<\/jats:italic>=\u00a0<\/jats:italic>38). After 3 cycles of IC<\/jats:styled-content>, patients were scheduled to receive cisplatin concurrent with definitive radiotherapy. T and N classification and smoking history were similar between the two groups and within p16\u2010positive and p16\u2010negative subsets. The median duration of follow\u2010up for living patients in the APF<\/jats:styled-content>\u2010C group was 43.5 (range: 30\u201358)\u00a0months versus 52 (range: 13\u201384)\u00a0months for TPF<\/jats:styled-content>\u2010C. The 2\u2010year DSS<\/jats:styled-content> for patients treated with APF<\/jats:styled-content>\u2010C was 96.7% [95% Confidence Interval (CI<\/jats:styled-content>): 85.2%, 99.8%] and with TPF<\/jats:styled-content>\u2010C was 77.6% (CI<\/jats:styled-content>: 62.6%, 89.7%) (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.0004). Disease progression that resulted in death was more frequent in the TPF<\/jats:styled-content>\u2010C group (39%) compared with the APF<\/jats:styled-content>\u2010C group (3%) when adjusted for competing risks of death from other causes (Gray's test, P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.0004). In p16 positive OPSCC<\/jats:styled-content>, the 2\u2010year DSS<\/jats:styled-content> for APF<\/jats:styled-content>\u2010C was 100% and for TPF<\/jats:styled-content>\u2010C was 74.6% (CI<\/jats:styled-content>: 47.4%, 94.6%) (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.0019) and the 2\u2010year OS<\/jats:styled-content> for APF<\/jats:styled-content>\u2010C was 94.1% (CI<\/jats:styled-content>: 65.0%, 99.2%) and for TPF<\/jats:styled-content>\u2010C was 74.6% (CI<\/jats:styled-content>: 39.8%, 91.1%) (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.013). In p16 negative HNSCC<\/jats:styled-content>, the 2\u2010year DSS<\/jats:styled-content> for APF<\/jats:styled-content>\u2010C was 91.7% (CI<\/jats:styled-content>: 67.6%, 99.6%) and for TPF<\/jats:styled-content>\u2010C was 82.6% (CI<\/jats:styled-content>: 64.4%, 94.8%) (P\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.092). A 2\u2010year DSS<\/jats:styled-content> and OS<\/jats:styled-content> were significantly better with a nab<\/jats:italic>\u2010paclitaxel\u2010based IC<\/jats:styled-content> regimen (APF<\/jats:styled-content>\u2010C) compared to a docetaxel\u2010based IC<\/jats:styled-content> regimen (TPF<\/jats:styled-content>\u2010C) in p16\u2010positive OPSCC<\/jats:styled-content>.<\/jats:p>","DOI":"10.1002\/cam4.382","type":"journal-article","created":{"date-parts":[[2015,1,26]],"date-time":"2015-01-26T06:33:20Z","timestamp":1422254000000},"page":"481-489","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Nab\u2010paclitaxel\u2010based compared to docetaxel\u2010based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck"],"prefix":"10.1002","volume":"4","author":[{"given":"Amy","family":"Schell","sequence":"first","affiliation":[{"name":"Division of Oncology Department of Internal Medicine Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ley","sequence":"additional","affiliation":[{"name":"Division of Oncology Department of Internal Medicine Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningying","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Biostatistics Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Trinkaus","sequence":"additional","affiliation":[{"name":"Division of Biostatistics Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya Marya","family":"Wildes","sequence":"additional","affiliation":[{"name":"Division of Oncology Department of Internal Medicine Washington University School of Medicine St. Louis Missouri"},{"name":"Alvin J Siteman Cancer Center Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Michel","sequence":"additional","affiliation":[{"name":"Division of Oncology Department of Internal Medicine Washington University School of Medicine St. Louis Missouri"},{"name":"Alvin J Siteman Cancer Center Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Thorstad","sequence":"additional","affiliation":[{"name":"Alvin J Siteman Cancer Center Washington University School of Medicine St. Louis Missouri"},{"name":"Department of Radiation Oncology Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiram","family":"Gay","sequence":"additional","affiliation":[{"name":"Alvin J Siteman Cancer Center Washington University School of Medicine St. Louis Missouri"},{"name":"Department of Radiation Oncology Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Surgical Pathology Department of Pathology and Immunology Washington University School of Medicine St. Louis Missouri"},{"name":"Department of Otolaryngology\u2010Head & Neck Surgery Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Rich","sequence":"additional","affiliation":[{"name":"Alvin J Siteman Cancer Center Washington University School of Medicine St. Louis Missouri"},{"name":"Department of Otolaryngology\u2010Head & Neck Surgery Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Diaz","sequence":"additional","affiliation":[{"name":"Alvin J Siteman Cancer Center Washington University School of Medicine St. Louis Missouri"},{"name":"Department of Otolaryngology\u2010Head & Neck Surgery Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randal C.","family":"Paniello","sequence":"additional","affiliation":[{"name":"Alvin J Siteman Cancer Center Washington University School of Medicine St. Louis Missouri"},{"name":"Department of Otolaryngology\u2010Head & Neck Surgery Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Nussenbaum","sequence":"additional","affiliation":[{"name":"Alvin J Siteman Cancer Center Washington University School of Medicine St. Louis Missouri"},{"name":"Department of Otolaryngology\u2010Head & Neck Surgery Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Adkins","sequence":"additional","affiliation":[{"name":"Division of Oncology Department of Internal Medicine Washington University School of Medicine St. Louis Missouri"},{"name":"Alvin J Siteman Cancer Center Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,26]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"SEER Cancer Statistics Review, 1975\u20132009(Vintage 2009 Populations)","author":"Howlader N.","year":"2012"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070956"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071028"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.09109"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27741"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.128.10.1172"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181e84652"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn011"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176350951"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70011-1"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70279-5"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.6423"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.1990"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00152.2002"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20608"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12138"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0103"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2721"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0537"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1206923"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1208130"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1111963108"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1512"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.4.265"},{"key":"e_1_2_6_27_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.5500","article-title":"DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5\u2010fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2\/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN)","volume":"30","author":"Cohen E. W.","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1592"},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.6005","article-title":"E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)\u2010associated resectable squamous cell carcinoma of the oropharynx (OPSCC)","volume":"31","author":"Marur S.","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.0425"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.382","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.382","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.382","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T19:45:43Z","timestamp":1696621543000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,26]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1002\/cam4.382"],"URL":"https:\/\/doi.org\/10.1002\/cam4.382","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,26]]},"assertion":[{"value":"2014-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}